The M1 frameshift neoantigen derived from TGFBR2, the first described cMS driver mutation in MSI cancer and also the first ever frameshift neoantigen characterized for its immunological properties in MSI cancer in pioneering studies18,42,43, displays the highest IRS (28.57%). The gene discussed is TGFBR2; the disease is cancer.